Your Health, We Care
Release date: 2026-02-10 17:40:00 Article From: Lucius Laos Recommended: 10
Before taking selumetinib, tell your doctor about all your medical conditions, including: heart problems, eye problems, and liver problems.
Your doctor should perform a pregnancy test before you start treatment.
Use effective contraception during treatment and for 1 week after the last dose.
If you become pregnant or think you may be pregnant during treatment, tell your doctor right away.
Use effective contraception during treatment and for 1 week after the last dose.
It is not known if selumetinib passes into breast milk. Do not breastfeed during treatment and for 1 week after the last dose. Talk to your doctor about the best way to feed your baby during this time.
Tell your doctor about all the medicines you take, including prescription and over‑the‑counter medicines, vitamins, or herbal supplements. Certain medicines may affect how selumetinib works. Especially tell your doctor if you are taking supplements containing vitamin E, aspirin, anticoagulants, or other medicines used to treat blood clots. Selumetinib capsules contain vitamin E, which may increase the risk of bleeding.
Keep in the original package, tightly closed, and keep away from children.
Store at room temperature, away from heat and moisture (do not store in the bathroom).
Do not remove the desiccant from the bottle.
Keep all medicines out of sight and reach of children, with the bottle cap tightly closed. Do not flush unwanted medicines down the toilet. Dispose of them through a medicine take‑back program; ask your pharmacist for more information.
Keep all scheduled follow‑up appointments, eye exams, and laboratory tests so your doctor can monitor your body’s response to the medicine.
Do not give this medicine to other people.
Ask your pharmacist about refills.
Keep a list of all prescription and over‑the‑counter medicines, vitamins, and supplements you use. Carry the list with you to doctor visits or hospital stays for use in emergencies.
In case of an overdose, call the poison control center hotline or search online for information. If the patient is unconscious, having seizures, having trouble breathing, or cannot be woken up, contact a pharmacist immediately.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：1002025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3792024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：872025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：1102025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：1052025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：1192025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：1152025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：1112025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
